ACTON, Mass., Dec. 3, 2013 —Cognoptix President and CEO Paul Hartung has been honored as “Emerging Medical Technologies Innovator of the Month” by Life Science Intelligence® (“LSI”).
The accolade comes on the heels of clinical data presented recently at the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) scientific meeting related to the strong results of a multi-site clinical trial of the Cognoptix SAPPHIRE II eye test, which is designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (Ab) signature in their eyes.
“I am gratified by this distinction from LSI, which recognizes the great progress we have made in developing an early-stage, non-invasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur,” said Hartung.
Mr. Hartung, who orchestrated the first-ever Series A syndicated Angel deal in the Northeast, has closed Seed, Series A, Series B and Series C rounds of financing for Cognoptix totaling $17 million with an international Angel and VC syndicate. He has extensive management experience launching successful startup businesses and leading Fortune 500 organizations. In addition to Cognoptix, Hartung has been an executive at Motorola (Winphoria Networks), 3Com Corporation, Summit Technology, Trumpf Industrial Lasers and Laser Fare, building scalable operations, improving customer satisfaction, corporate profitability and time-to-market. He holds a Master of Science degree in Mechanical Engineering, with honors, from the Massachusetts Institute of Technology (MIT).
About Life Science Intelligence®
Life Science Intelligence (LSI) delivers high-quality global market intelligence products to medical technology executives, entrepreneurs, and investors. LSI produces its own information products and partners with select top-tier information companies to distribute their high-end information. www.lifescienceintelligence.com
About Cognoptix
Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD). Its investors include Inventages Venture Capital, one of the world’s largest life sciences-, nutrition- and wellness-focused venture capital firms; Launchpad Venture Group, a Boston-based angel investment firm that provides funding to early-stage companies; and Maine Angels, accredited private equity investors in promising New England entrepreneurs and companies.
NOTE: The SAPPHIRE II system is approved for investigational use only in the United States.
Help employers find you! Check out all the jobs and post your resume.
